Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Summary
Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stag...
Description
Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stag...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source